Showing results (31-40 of 211) with videos related to
Sort By:
Pageof 22
The Journal of Clinical Investigation|December 15, 2021
The role of estrogen receptor signaling in suppressing the immune response to cancerJames M Rae, Marc E LippmanThe Oncologist|April 26, 2012
Tamoxifen and CYP2D6: a contradiction of dataDaniel L Hertz, Howard L McLeod, William J IrvinPharmacogenetics and Genomics|August 2, 2026
Association of UGT and CYP genotype-predicted activity with tyrosine kinase inhibitor toxicityApril T Moy, Lia E D'Angelo, Daniel L HertzPharmacogenomics|April 6, 2013
Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapyStefanie D Krens, Howard L McLeod, Daniel L HertzBreast (Edinburgh, Scotland)|November 17, 2009
Pharmacogenetics of breast cancer therapiesDaniel L Hertz, Howard L McLeod, Janelle M HoskinsThe Pharmacogenomics Journal|October 17, 2019
Challenges to assess substrate-dependent allelic effects in CYP450 enzymes and the potential clinical implicationsLauren A Marcath, Amy L Pasternak, Daniel L HertzPharmacogenomics|July 24, 2020
Genetic variation in Charcot-Marie-Tooth genes contributes to sensitivity to paclitaxel-induced peripheral neuropathyYongzhen Chen, Fang Fang, Kelley M Kidwell, et al.Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 1, 2022
Genome-wide association study of aromatase inhibitor discontinuation due to musculoskeletal symptomsDaniel L Hertz, Julie A Douglas, Robert M Miller, et al.Breast Cancer Research and Treatment|February 13, 2019
Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletionLandry K Kamdem, Jingyue Xi, Brandi L Clark, et al.Pharmacogenomics|June 14, 2019
Effects of SLCO1B1 polymorphisms on plasma estrogen concentrations in women with breast cancer receiving aromatase inhibitors exemestane and letrozoleJacqueline M Dempsey, Kelley M Kidwell, Christina L Gersch, et al.Pageof 22